{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:56:22Z","timestamp":1781632582603,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Project of Science and Technology Department of Sichuan Province","award":["2023YFS0307"],"award-info":[{"award-number":["2023YFS0307"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the uncontrolled growth of immature myeloid cells, often with a poor prognosis due to therapy resistance. This study investigated the prognostic significance of\n                      <jats:italic>SRSF2<\/jats:italic>\n                      mutations in AML and their impact on chemotherapeutic drug sensitivity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The prognostic value of\n                      <jats:italic>SRSF2<\/jats:italic>\n                      mutations was analyzed in AML patients.\n                      <jats:italic>SRSF2<\/jats:italic>\n                      -mutant cell models were generated via lentiviral transduction for drug sensitivity testing. Xenograft mice were used to assess daunorubicin (DNR) efficacy. Mechanistic studies included transcriptomics, splicing analysis, mRNA stability, polysome profiling, RNA immunoprecipitation, and metabolic assays to identify targetable resistance pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical analysis revealed that\n                      <jats:italic>SRSF2<\/jats:italic>\n                      mutations decreased the survival of AML patients.\n                      <jats:italic>In vitro<\/jats:italic>\n                      experiments demonstrated that\n                      <jats:italic>SRSF2<\/jats:italic>\n                      mutation reduced the sensitivity of AML cells to drugs such as DNR and homoharringtonine but did not affect the response to venetoclax. In mouse models, DNR treatment was effective against wild-type AML but showed significantly reduced efficacy in suppressing tumors and improving survival in\n                      <jats:italic>SRSF2<\/jats:italic>\n                      -mutant AML. Mechanistically,\n                      <jats:italic>SRSF2<\/jats:italic>\n                      mutation impaired the interaction between the\n                      <jats:italic>SRSF2<\/jats:italic>\n                      protein and\n                      <jats:italic>THBS1<\/jats:italic>\n                      mRNA, prolonging the\n                      <jats:italic>THBS1<\/jats:italic>\n                      mRNA half-life and enhancing its translation efficiency, leading to THBS1 protein accumulation. Additionally, the mutation altered the splicing pattern of\n                      <jats:italic>ETV7<\/jats:italic>\n                      and upregulated its expression, potentially mediating DNR resistance. Metabolic analysis revealed that mutant cells presented increased spare respiratory capacity, supporting energy demands under stress. Inhibition of the PDGFB pathway (CP-673451) synergistically enhanced the cytotoxic effect of DNR on mutant cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>SRSF2<\/jats:italic>\n                      mutations promoted DNR resistance through multiple mechanisms, and targeted combination therapy with PDGFB pathway inhibitors may represent a novel strategy to improve therapeutic outcomes in patients with mutations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03649-y","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:55:50Z","timestamp":1769759750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization"],"prefix":"10.1186","volume":"45","author":[{"given":"Wu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"17","key":"3649_CR1","doi-asserted-by":"publisher","first-page":"9201","DOI":"10.1080\/07391102.2023.2250460","volume":"42","author":"E Belghalia","year":"2024","unstructured":"Belghalia E, Ouabane M, El BS, et al. In Silico research on new sulfonamide derivatives as BRD4 inhibitors targeting acute myeloid leukemia using various computational techniques including 3D-QSAR, HQSAR, molecular docking, ADME\/Tox, and molecular dynamics. J Biomol Struct Dyn. 2024;42(17):9201\u201319. https:\/\/doi.org\/10.1080\/07391102.2023.2250460.","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"3649_CR2","doi-asserted-by":"publisher","first-page":"195062","DOI":"10.1016\/j.bbagrm.2024.195062","volume":"1867","author":"A Chrysostomou","year":"2024","unstructured":"Chrysostomou A, Furlan C, Saccenti E. Machine learning based analysis of single-cell data reveals evidence of subject-specific single-cell gene expression profiles in acute myeloid leukaemia patients and healthy controls. Biochim Biophys Acta Gene Regul Mech. 2024;1867(4):195062. https:\/\/doi.org\/10.1016\/j.bbagrm.2024.195062.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"11","key":"3649_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"3","key":"3649_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ajh.26812","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B, Martelli MP. Comparison of the international consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Am J Hematol. 2023;98(3):481\u201392. https:\/\/doi.org\/10.1002\/ajh.26812.","journal-title":"Am J Hematol"},{"issue":"2","key":"3649_CR5","doi-asserted-by":"publisher","first-page":"100397","DOI":"10.1016\/j.modpat.2023.100397","volume":"37","author":"S Loghavi","year":"2024","unstructured":"Loghavi S, Kanagal-Shamanna R, Khoury JD, et al. Fifth edition of the world health classification of tumors of the hematopoietic and lymphoid tissue: myeloid Neoplasms. Mod Pathol. 2024;37(2):100397. https:\/\/doi.org\/10.1016\/j.modpat.2023.100397.","journal-title":"Mod Pathol"},{"issue":"1","key":"3649_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ajh.26772","volume":"98","author":"A Orazi","year":"2023","unstructured":"Orazi A, Hasserjian RP, Cazzola M, et al. International consensus classification for myeloid neoplasms at-a-glance. Am J Hematol. 2023;98(1):6\u201310. https:\/\/doi.org\/10.1002\/ajh.26772.","journal-title":"Am J Hematol"},{"issue":"1","key":"3649_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-024-01571-4","volume":"17","author":"W Xiao","year":"2024","unstructured":"Xiao W, Nardi V, Stein E, et al. A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC. J Hematol Oncol. 2024;17(1):56. https:\/\/doi.org\/10.1186\/s13045-024-01571-4.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3649_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29. https:\/\/doi.org\/10.1186\/s13045-023-01424-6.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3649_CR9","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1038\/s41467-024-46547-7","volume":"15","author":"D Rombaut","year":"2024","unstructured":"Rombaut D, Lef\u00e8vre C, Rached T, et al. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation. Nat Commun. 2024;15(1):3016. https:\/\/doi.org\/10.1038\/s41467-024-46547-7.","journal-title":"Nat Commun"},{"issue":"1","key":"3649_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s11658-024-00594-6","volume":"29","author":"M Bei","year":"2024","unstructured":"Bei M, Xu J. SR proteins in cancer: function, regulation, and small inhibitor. Cell Mol Biol Lett. 2024;29(1):78. https:\/\/doi.org\/10.1186\/s11658-024-00594-6.","journal-title":"Cell Mol Biol Lett"},{"issue":"11","key":"3649_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1101\/gad.1934910","volume":"24","author":"JL Manley","year":"2010","unstructured":"Manley JL, Krainer AR. A rational nomenclature for serine\/arginine-rich protein splicing factors (SR proteins). Genes Dev. 2010;24(11):1073\u20134. https:\/\/doi.org\/10.1101\/gad.1934910.","journal-title":"Genes Dev"},{"issue":"6","key":"3649_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.seminhematol.2024.10.005","volume":"61","author":"CC Tseng","year":"2024","unstructured":"Tseng CC, Obeng EA. RNA splicing as a therapeutic target in myelodysplastic syndromes. Semin Hematol. 2024;61(6):431\u201341. https:\/\/doi.org\/10.1053\/j.seminhematol.2024.10.005.","journal-title":"Semin Hematol"},{"key":"3649_CR13","doi-asserted-by":"publisher","unstructured":"Sha R, Guo R, Duan H, et al. SRSF2 is a key player in orchestrating the directional migration and differentiation of myod progenitors during skeletal muscle development. Elife. 2024;13. https:\/\/doi.org\/10.7554\/eLife.98175.","DOI":"10.7554\/eLife.98175"},{"issue":"1","key":"3649_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s42003-020-0893-5","volume":"3","author":"C Zhang","year":"2020","unstructured":"Zhang C, Shen L, Yuan W, et al. Loss of SRSF2 triggers hepatic progenitor cell activation and tumor development in mice. Commun Biol. 2020;3(1):210. https:\/\/doi.org\/10.1038\/s42003-020-0893-5.","journal-title":"Commun Biol"},{"issue":"6","key":"3649_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood-2017-01-762393","volume":"131","author":"A Kon","year":"2018","unstructured":"Kon A, Yamazaki S, Nannya Y, et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018;131(6):621\u201335. https:\/\/doi.org\/10.1182\/blood-2017-01-762393.","journal-title":"Blood"},{"key":"3649_CR16","doi-asserted-by":"publisher","unstructured":"Wei Z, Wang Y, Ma W et al. Serine-arginine splicing factor 2 promotes oesophageal cancer progression by regulating alternative splicing of interferon regulatory factor 3. RNA Biol, 2023,20(1):359\u2013367.https:\/\/doi.org\/10.1080\/15476286. 2023.2223939.","DOI":"10.1080\/15476286"},{"key":"3649_CR17","doi-asserted-by":"publisher","unstructured":"Bouligny IM, Maher KR, Grant S. Secondary-Type mutations in acute myeloid leukemia: updates from ELN 2022. Cancers (Basel). 2023;15(13). https:\/\/doi.org\/10.3390\/cancers15133292.","DOI":"10.3390\/cancers15133292"},{"issue":"5\u20136","key":"3649_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1101\/gad.332270.119","volume":"34","author":"MA Rahman","year":"2020","unstructured":"Rahman MA, Lin KT, Bradley RK, et al. Recurrent SRSF2 mutations in MDS affect both splicing and NMD. Genes Dev. 2020;34(5\u20136):413\u201327. https:\/\/doi.org\/10.1101\/gad.332270.119.","journal-title":"Genes Dev"},{"issue":"4","key":"3649_CR19","doi-asserted-by":"publisher","first-page":"109443","DOI":"10.1016\/j.isci.2024.109443","volume":"27","author":"M Su","year":"2024","unstructured":"Su M, Fleischer T, Grosheva I, et al. Targeting SRSF2 mutations in leukemia with RKI-1447: A strategy to impair cellular division and nuclear structure. iScience. 2024;27(4):109443. https:\/\/doi.org\/10.1016\/j.isci.2024.109443.","journal-title":"iScience"},{"issue":"8","key":"3649_CR20","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1007\/s11033-023-08597-w","volume":"50","author":"W Jia","year":"2023","unstructured":"Jia W, Guo X, Wei Y, et al. Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia. Mol Biol Rep. 2023;50(8):6601\u201310. https:\/\/doi.org\/10.1007\/s11033-023-08597-w.","journal-title":"Mol Biol Rep"},{"issue":"7","key":"3649_CR21","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3324\/haematol.2023.283661","volume":"109","author":"AG Jain","year":"2024","unstructured":"Jain AG, Ball S, Aguirre L, et al. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024;109(7):2157\u201364. https:\/\/doi.org\/10.3324\/haematol.2023.283661.","journal-title":"Haematologica"},{"issue":"3","key":"3649_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/ajh.24973","volume":"93","author":"G Venton","year":"2018","unstructured":"Venton G, Courtier F, Charbonnier A, et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018;93(3):330\u20138. https:\/\/doi.org\/10.1002\/ajh.24973.","journal-title":"Am J Hematol"},{"key":"3649_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01999-6","author":"E Jahn","year":"2023","unstructured":"Jahn E, Saadati M, Fenaux P, et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023. https:\/\/doi.org\/10.1038\/s41375-023-01999-6.","journal-title":"Leukemia"},{"issue":"9","key":"3649_CR24","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/s41375-019-0416-x","volume":"33","author":"MY Follo","year":"2019","unstructured":"Follo MY, Pellagatti A, Armstrong RN, et al. Response of high-risk MDS to Azacitidine and Lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes. Leukemia. 2019;33(9):2276\u201390. https:\/\/doi.org\/10.1038\/s41375-019-0416-x.","journal-title":"Leukemia"},{"issue":"7","key":"3649_CR25","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2018","unstructured":"Rothenberg-Thurley M, Amler S, Goerlich D, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598\u2013608. https:\/\/doi.org\/10.1038\/s41375-018-0034-z.","journal-title":"Leukemia"},{"issue":"9","key":"3649_CR26","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367\u201376. https:\/\/doi.org\/10.1182\/blood-2014-11-610543.","journal-title":"Blood"},{"key":"3649_CR27","doi-asserted-by":"publisher","unstructured":"Kang D, Jung J, Park S, et al. Genetic characteristics according to subgroup of acute myeloid leukemia with Myelodysplasia-Related Changes. J Clin Med. 2022;11(9). https:\/\/doi.org\/10.3390\/jcm11092378.","DOI":"10.3390\/jcm11092378"},{"issue":"15","key":"3649_CR28","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/bloodadvances.2019000306","volume":"3","author":"T Murphy","year":"2019","unstructured":"Murphy T, Zou J, Daher-Reyes GS, et al. Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. Blood Adv. 2019;3(15):2307\u201311. https:\/\/doi.org\/10.1182\/bloodadvances.2019000306.","journal-title":"Blood Adv"},{"issue":"23","key":"3649_CR29","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid Leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1516192.","journal-title":"N Engl J Med"},{"issue":"11","key":"3649_CR30","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/leu.2016.126","volume":"30","author":"VI Gaidzik","year":"2016","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30(11):2160\u20138. https:\/\/doi.org\/10.1038\/leu.2016.126.","journal-title":"Leukemia"},{"issue":"2","key":"3649_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.arthro.2021.06.037","volume":"38","author":"JW Chen","year":"2022","unstructured":"Chen JW, Maldonado DR, Kowalski BL, et al. Best practice guidelines for propensity score methods in medical research: consideration on Theory, Implementation, and reporting. Review Arthrosc. 2022;38(2):632\u201342. https:\/\/doi.org\/10.1016\/j.arthro.2021.06.037.","journal-title":"Review Arthrosc"},{"key":"3649_CR32","doi-asserted-by":"publisher","unstructured":"Gandin V, Sikstr\u00f6m K, Alain T et al. Polysome fractionation and analysis of mammalian translatomes on a genome-wide scale. J Vis Exp, 2014(87). https:\/\/doi.org\/10.3791\/51455","DOI":"10.3791\/51455"},{"issue":"5","key":"3649_CR33","doi-asserted-by":"publisher","first-page":"101252","DOI":"10.1016\/j.gendis.2024.101252","volume":"11","author":"J Fan","year":"2024","unstructured":"Fan J, Li Z, Pei L, et al. Post-transcriptional regulation of DEAD-box RNA helicases in hematopoietic malignancies. Genes Dis. 2024;11(5):101252. https:\/\/doi.org\/10.1016\/j.gendis.2024.101252.","journal-title":"Genes Dis"},{"key":"3649_CR34","doi-asserted-by":"publisher","first-page":"108680DOI","DOI":"10.1016\/j.pharmthera.2024.108680","volume":"260","author":"X Wang","year":"2024","unstructured":"Wang X, Lv X, Ma J, et al. UFMylation: an integral post-translational modification for the regulation of proteostasis and cellular functions. Pharmacol Ther. 2024;260:108680DOI. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108680.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"3649_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.molcel.2023.01.013","volume":"83","author":"P Dave","year":"2023","unstructured":"Dave P, Roth G, Griesbach E, et al. Single-molecule imaging reveals translation-dependent destabilization of mRNAs. Mol Cell. 2023;83(4):589\u2013DOI606. https:\/\/doi.org\/10.1016\/j.molcel.2023.01.013.","journal-title":"Mol Cell"},{"issue":"11","key":"3649_CR36","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.cell.2023.04.026","volume":"186","author":"J Zhang","year":"2023","unstructured":"Zhang J, Simpson CM, Berner J, et al. Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway. Cell. 2023;186(11):2361\u201379. https:\/\/doi.org\/10.1016\/j.cell.2023.04.026.","journal-title":"Cell"},{"key":"3649_CR37","doi-asserted-by":"publisher","first-page":"669188","DOI":"10.3389\/fcell.2021.669188","volume":"9","author":"K Kalra","year":"2021","unstructured":"Kalra K, Eberhard J, Farbehi N, et al. Role of PDGF-A\/B ligands in cardiac repair after myocardial Infarction. Front Cell Dev Biol. 2021;9:669188. https:\/\/doi.org\/10.3389\/fcell.2021.669188.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"3649_CR38","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.7150\/ijbs.58888","volume":"17","author":"K Li","year":"2021","unstructured":"Li K, Wang Z. Splicing factor SRSF2-centric gene regulation. Int J Biol Sci. 2021;17(7):1708\u201315. https:\/\/doi.org\/10.7150\/ijbs.58888.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"3649_CR39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000530940","volume":"91","author":"C Faria","year":"2024","unstructured":"Faria C, Tzankov A. Progression in myeloid neoplasms: beyond the myeloblast . Pathobiology. 2024;91(1):55\u201375. https:\/\/doi.org\/10.1159\/000530940.","journal-title":"Pathobiology"},{"issue":"19","key":"3649_CR40","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1016\/j.molcel.2024.07.019","volume":"84","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Ai Y, Abdel-Wahab O. Molecular impact of mutations in RNA splicing factors in cancer. Mol Cell. 2024;84(19):3667\u201380. https:\/\/doi.org\/10.1016\/j.molcel.2024.07.019.","journal-title":"Mol Cell"},{"key":"3649_CR41","doi-asserted-by":"publisher","unstructured":"Liu L, Lv Z, Wang M, et al. HBV enhances Sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-Mediated abnormal PCLAF Splicing. Int J Mol Sci. 2023;24(4). https:\/\/doi.org\/10.3390\/ijms24043263.","DOI":"10.3390\/ijms24043263"},{"issue":"6","key":"3649_CR42","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s13402-024-01023-8","volume":"47","author":"JM Wang","year":"2024","unstructured":"Wang JM, Liu N, Wei XJ, et al. Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin. Cell Oncol (Dordr). 2024;47(6):2349\u201366. https:\/\/doi.org\/10.1007\/s13402-024-01023-8.","journal-title":"Cell Oncol (Dordr)"},{"issue":"22","key":"3649_CR43","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1038\/s41388-020-1292-6","volume":"39","author":"I Pellarin","year":"2020","unstructured":"Pellarin I, Dall\u2019Acqua A, Gambelli A, et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity. Oncogene. 2020;39(22):4390\u2013403. https:\/\/doi.org\/10.1038\/s41388-020-1292-6.","journal-title":"Oncogene"},{"issue":"8","key":"3649_CR44","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/bloodadvances.2020004173","volume":"5","author":"CA Lachowiez","year":"2021","unstructured":"Lachowiez CA, Loghavi S, Furudate K, et al. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021;5(8):2173\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2020004173.","journal-title":"Blood Adv"},{"issue":"11","key":"3649_CR45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41419-018-1148-y","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Fang L, Jiang J, et al. The cisplatin-induced LncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018;9(11):1103. https:\/\/doi.org\/10.1038\/s41419-018-1148-y.","journal-title":"Cell Death Dis"},{"key":"3649_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2017.03.013","volume":"396","author":"H K\u0119dzierska","year":"2017","unstructured":"K\u0119dzierska H, Piekie\u0142ko-Witkowska A. Splicing factors of SR and HnRNP families as regulators of apoptosis in cancer. Cancer Lett. 2017;396:53\u201365. https:\/\/doi.org\/10.1016\/j.canlet.2017.03.013.","journal-title":"Cancer Lett"},{"key":"3649_CR47","doi-asserted-by":"publisher","unstructured":"Kale A, Rogers NM, Ghimire K. Thrombospondin-1 CD47 signalling: from mechanisms to Medicine. Int J Mol Sci. 2021;22(8). https:\/\/doi.org\/10.3390\/ijms22084062.","DOI":"10.3390\/ijms22084062"},{"key":"3649_CR48","doi-asserted-by":"publisher","unstructured":"Kaur S, Bronson SM, Pal-Nath D, et al. Functions of Thrombospondin-1 in the tumor Microenvironment. Int J Mol Sci. 2021;22(9). https:\/\/doi.org\/10.3390\/ijms22094570.","DOI":"10.3390\/ijms22094570"},{"issue":"1","key":"3649_CR49","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1038\/s41467-023-41095-y","volume":"14","author":"M Omatsu","year":"2023","unstructured":"Omatsu M, Nakanishi Y, Iwane K, et al. THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. Nat Commun. 2023;14(1):5534. https:\/\/doi.org\/10.1038\/s41467-023-41095-y.","journal-title":"Nat Commun"},{"key":"3649_CR50","doi-asserted-by":"publisher","unstructured":"Wen Z, Zhang Y, Wang X, et al. THBS1-Mediated degradation of collagen via the PI3K\/AKT pathway facilitates the metastasis and poor prognosis of OSCC. Int J Mol Sci. 2023;24(17). https:\/\/doi.org\/10.3390\/ijms241713312.","DOI":"10.3390\/ijms241713312"},{"issue":"22","key":"3649_CR51","doi-asserted-by":"publisher","first-page":"6182","DOI":"10.1016\/j.cell.2024.08.014","volume":"187","author":"JH Lee","year":"2024","unstructured":"Lee JH, S\u00e1nchez-Rivera FJ, He L, et al. TGF-\u03b2 and RAS jointly unmask primed enhancers to drive metastasis. Cell. 2024;187(22):6182\u201399. https:\/\/doi.org\/10.1016\/j.cell.2024.08.014.","journal-title":"Cell"},{"issue":"1","key":"3649_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.14336\/AD.2023.0420","volume":"15","author":"J Yan","year":"2024","unstructured":"Yan J, Xiao G, Yang C, et al. Cancer-Associated fibroblasts promote lymphatic metastasis in cholangiocarcinoma via the PDGF-BB\/PDGFR-\u03b2 mediated paracrine signaling Network. Aging Dis. 2024;15(1):369\u201389. https:\/\/doi.org\/10.14336\/AD.2023.0420.","journal-title":"Aging Dis"},{"issue":"8","key":"3649_CR53","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.ccell.2023.07.001","volume":"41","author":"D Ceresa","year":"2023","unstructured":"Ceresa D, Alessandrini F, Lucchini S, et al. Early clonal extinction in glioblastoma progression revealed by genetic barcoding. Cancer Cell. 2023;41(8):1466\u201379. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.001.","journal-title":"Cancer Cell"},{"issue":"26","key":"3649_CR54","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood.2023022079","volume":"143","author":"HY Lin","year":"2024","unstructured":"Lin HY, Mohammadhosseini M, McClatchy J, et al. The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1\u03b2-mediated AML progression. Blood. 2024;143(26):2749\u201362. https:\/\/doi.org\/10.1182\/blood.2023022079.","journal-title":"Blood"},{"issue":"6","key":"3649_CR55","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1158\/0008-5472.CAN-18-0921","volume":"79","author":"BZ Carter","year":"2019","unstructured":"Carter BZ, Mak PY, Wang X, et al. An ARC-Regulated IL1\u03b2\/Cox-2\/PGE2\/ \u03b2-Catenin\/ARC circuit controls Leukemia-Microenvironment interactions and confers drug resistance in AML. Cancer Res. 2019;79(6):1165\u201377. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0921.","journal-title":"Cancer Res"},{"key":"3649_CR56","doi-asserted-by":"publisher","unstructured":"Chen Z, Giotti B, Kaluzova M, et al. A paracrine circuit of IL-1\u03b2\/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression. J Clin Invest. 2023;133(22). https:\/\/doi.org\/10.1172\/JCI163802.","DOI":"10.1172\/JCI163802"},{"issue":"37","key":"3649_CR57","doi-asserted-by":"publisher","first-page":"e1973173175","DOI":"10.1073\/pnas.2321794121","volume":"121","author":"T Le Voyer","year":"2024","unstructured":"Le Voyer T, Maglorius RM, Moriya K, et al. Inherited human RelB deficiency impairs innate and adaptive immunity to infection. Proc Natl Acad Sci U S A. 2024;121(37):e1973173175. https:\/\/doi.org\/10.1073\/pnas.2321794121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3649_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-022-02243-2","volume":"41","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhu S, Du Y, et al. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J Exp Clin Cancer Res. 2022;41(1):66. https:\/\/doi.org\/10.1186\/s13046-022-02243-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"3649_CR59","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.redox.2023.102952","volume":"68","author":"Z Xu","year":"2023","unstructured":"Xu Z, Wang X, Sun W, et al. RelB-activated GPX4 inhibits ferroptosis and confers Tamoxifen resistance in breast cancer. Redox Biol. 2023;68:102952. https:\/\/doi.org\/10.1016\/j.redox.2023.102952.","journal-title":"Redox Biol"},{"issue":"1","key":"3649_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13578-020-00521-0","volume":"11","author":"R Frazzi","year":"2021","unstructured":"Frazzi R. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. Cell Biosci. 2021;11(1):8. https:\/\/doi.org\/10.1186\/s13578-020-00521-0.","journal-title":"Cell Biosci"},{"issue":"2","key":"3649_CR61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3324\/haematol.2019.219550","volume":"105","author":"F Diop","year":"2020","unstructured":"Diop F, Moia R, Favini C, et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020;105(2):448\u201356. https:\/\/doi.org\/10.3324\/haematol.2019.219550.","journal-title":"Haematologica"},{"issue":"5","key":"3649_CR62","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by Mutant-Specific effects on exon Recognition. Cancer Cell. 2015;27(5):617\u201330. https:\/\/doi.org\/10.1016\/j.ccell.2015.04.006.","journal-title":"Cancer Cell"},{"key":"3649_CR63","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-biochem-052621-091808","volume":"92","author":"Q Wu","year":"2023","unstructured":"Wu Q, Bazzini AA. Translation and mRNA stability Control. Annu Rev Biochem. 2023;92:227\u201345. https:\/\/doi.org\/10.1146\/annurev-biochem-052621-091808.","journal-title":"Annu Rev Biochem"},{"issue":"34","key":"3649_CR64","doi-asserted-by":"publisher","first-page":"E4726","DOI":"10.1073\/pnas.1514105112","volume":"112","author":"J Zhang","year":"2015","unstructured":"Zhang J, Lieu YK, Ali AM, et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A. 2015;112(34):E4726\u201334. https:\/\/doi.org\/10.1073\/pnas.1514105112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"3649_CR65","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1016\/j.molcel.2023.11.003","volume":"83","author":"HL Ma","year":"2023","unstructured":"Ma HL, Bizet M, Soares DCC, et al. SRSF2 plays an unexpected role as reader of m(5)C on mRNA, linking epitranscriptomics to cancer. Mol Cell. 2023;83(23):4239\u201354. https:\/\/doi.org\/10.1016\/j.molcel.2023.11.003.","journal-title":"Mol Cell"},{"key":"3649_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00892-0","author":"J Cheng","year":"2025","unstructured":"Cheng J, Xiao Y, Peng T, et al. ETV7 limits the antiviral and antitumor efficacy of CD8(+) T cells by diverting their fate toward exhaustion. Nat Cancer. 2025. https:\/\/doi.org\/10.1038\/s43018-024-00892-0.","journal-title":"Nat Cancer"},{"issue":"1","key":"3649_CR67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s10142-023-01282-y","volume":"24","author":"B Chai","year":"2024","unstructured":"Chai B, Li Y, Guo Y, et al. ETV7 promotes colorectal cancer progression through upregulation of IFIT3. Funct Integr Genomics. 2024;24(1):8. 10.1007\/s 10142-023-01282-y.","journal-title":"Funct Integr Genomics"},{"issue":"4","key":"3649_CR68","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41419-023-05718-y","volume":"14","author":"EM Me\u0161kyt\u0117","year":"2023","unstructured":"Me\u0161kyt\u0117 EM, Pezz\u00e8 L, Bartolomei L, et al. ETV7 reduces inflammatory responses in breast cancer cells by repressing the TNFR1\/NF-\u03baB axis. Cell Death Dis. 2023;14(4):263. https:\/\/doi.org\/10.1038\/s41419-023-05718-y.","journal-title":"Cell Death Dis"},{"issue":"7","key":"3649_CR69","doi-asserted-by":"publisher","first-page":"e2202956","DOI":"10.1002\/advs.202202956","volume":"10","author":"J Li","year":"2023","unstructured":"Li J, Xia Q, Di C, et al. Tumor Cell-Intrinsic CD96 mediates chemoresistance and cancer stemness by regulating mitochondrial fatty acid \u03b2-Oxidation. Adv Sci (Weinh). 2023;10(7):e2202956. https:\/\/doi.org\/10.1002\/advs.202202956.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3649_CR70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bjh.16044","volume":"187","author":"J Ma","year":"2019","unstructured":"Ma J, Liu B, Yu D, et al. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation. Br J Haematol. 2019;187(1):49\u201364. https:\/\/doi.org\/10.1111\/bjh.16044.","journal-title":"Br J Haematol"},{"issue":"7","key":"3649_CR71","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, et al. Chemotherapy-Resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative Metabolism. Cancer Discov. 2017;7(7):716\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0441.","journal-title":"Cancer Discov"},{"issue":"10","key":"3649_CR72","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/2159-8290.CD-19-1008","volume":"10","author":"N Aroua","year":"2020","unstructured":"Aroua N, Boet E, Ghisi M, et al. Extracellular ATP and CD39 activate cAMP-Mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid Leukemia. Cancer Discov. 2020;10(10):1544\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1008.","journal-title":"Cancer Discov"},{"key":"3649_CR73","doi-asserted-by":"publisher","first-page":"215582","DOI":"10.1016\/j.canlet.2022.215582","volume":"532","author":"R You","year":"2022","unstructured":"You R, Wang B, Chen P, et al. Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells. Cancer Lett. 2022;532:215582. https:\/\/doi.org\/10.1016\/j.canlet.2022.215582.","journal-title":"Cancer Lett"},{"issue":"Pt 2","key":"3649_CR74","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.semcancer.2022.03.025","volume":"86","author":"W Li","year":"2022","unstructured":"Li W, Deng X, Chen J. RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol. 2022;86(Pt 2):664\u201377. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.025.","journal-title":"Semin Cancer Biol"},{"key":"3649_CR75","doi-asserted-by":"publisher","unstructured":"Liu X, Devadiga SA, Stanley RF, et al. A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies. J Clin Invest. 2024;134(12). https:\/\/doi.org\/10.1172\/JCI175619.","DOI":"10.1172\/JCI175619"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03649-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03649-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:23:31Z","timestamp":1781630611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03649-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3649"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03649-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of the animal experiment was approved by the Animal Ethics Committee of West China Hospital of Sichuan University. The clinical data collection from patients was approved by the Biomedical Ethics Committee of West China Hospital, Sichuan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}